# US 2019/0169247 A1 · Retinal capillary regeneration with synthetic protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169247 A1
- Document ID: US20190169247A1
- Status: Published application
- Kind: A1
- Application number: 16/214,225
- Filed: 2018-12-10
- Published: 2019-06-06
- Earliest claimed: 2015-06-08
- Assignees: Retinal Solutions LLC
- Applicants: Retinal Solutions LLC
- Inventors: Kimberly Drenser; Michael T. Trese; Antonio Capone
- Web page: https://patentgrep.com/patent/US20190169247A1

## CPC

- C07K 14/4705: {stimulating, promoting or activating activity}
- A61K 38/1891: {Angiogenesic factors; Angiogenin}
- C07K 14/475: Growth factors; Growth regulators
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61P 27/02: Ophthalmic agents
- C07K 14/515: Angiogenesic factors; Angiogenin
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method is provided for capillary stabilization and vascular regeneration in retinal tissue. Capillary regeneration is accomplished with a protein that is a truncated norrin protein (synthetic). The truncated norrin protein has a longer half-life in the eye than native wild norrin proteins. Specific versions of the truncated norrin protein lack a cleavage site that an enzyme in the eye use to cleave to native norrin proteins and thereby shorten the useful life of the protein. The provided method encourages vascular development with an exogenous treatment of truncated norrin that have been investigated in oxygen-induced retinopathy (OIR) mice. The therapeutic feasibility of intravitreal injection of the norrin protein and its effect on retinal development by activating Wnt-signaling has also been shown.

## Claims

### Claim 1

A method for capillary stabilization and vascular regeneration in retinal tissue comprising:
exposing the retinal tissue to a norrin; and
allowing sufficient time for said norrin in the retinal tissue to result in capillary vascular regeneration.

### Claim 2 (depends on 1)

The method of claim 1, wherein the retinal vessel cells are in vivo in a subject.

### Claim 3 (depends on 2)

The method of claim 2, wherein exposing step is by intraocular injection.

### Claim 4 (depends on 2)

The method of claim 2, wherein exposing step is by systemic administration.

### Claim 5 (depends on 2)

The method of claim 2, wherein exposing step is by topical administration.

### Claim 6 (depends on 2)

The method of claim 2, wherein said subject is human.

### Claim 7 (depends on 2)

The method of claim 2, wherein said subject is one of: cow, horse, sheep, pig, goat, chicken, cat, dog, mouse, guinea pig, hamster, rabbit, rat, or a cell derived from one of the aforementioned.

### Claim 8 (depends on 1)

The method of claim 1, wherein said norrin is truncated.

### Claim 9 (depends on 1)

The method of claim 1, wherein said norrin is a polypeptide of SEQ ID. NO. 2.

### Claim 10 (depends on 1)

The method of claim 1, wherein said norrin is a fragment of SEQ ID. NO. 1 that binds a frizzled-4 receptor of the retinal vessel cells.

### Claim 11 (depends on 1)

The method of claim 1, wherein said norrin is recombinant.